Dramatic Decline of PSA and Symptom Improvement after Estramustine Withdrawal in a Hormone-refractory Prostate Cancer Patient / 대한비뇨기과학회지
Korean Journal of Urology
;
: 751-753, 2007.
Article
in Korean
| WPRIM
| ID: wpr-95019
ABSTRACT
In some patients with prostate cancer and who manifest disease progression during maximal androgen blockade(MAB) therapy, discontinuation of antiandrogen treatment might result in a significant fall in the level of serum prostate-specific antigen(PSA), and this is often correlated with clinical improvement(antiandrogen withdrawal syndrome). However, a decline in the PSA level after the withdrawal of estramustine phosphate is extremely rare. We report here on a case of dramatic decline in the PSA level after withdrawal of estramustine phosphate in a patient with hormone refractory prostate cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostate
/
Prostatic Neoplasms
/
Disease Progression
/
Drug Therapy
/
Estramustine
Type of study:
Diagnostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Urology
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS